secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001159036-23-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M
------------------------------------------------------------

- Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).
- Q4 GAAP diluted EPS $0.42; non-GAAP diluted EPS $0.48. Full-year GAAP EPS $1.44; non-GAAP EPS $2.21.
- Record Q4 royalty revenue $106M (+69% YoY); full-year royalties $360.5M (+77% YoY).
- 2023 guidance: revenue $815-845M (23-28% growth), EBITDA $415-440M (>30% growth), non-GAAP EPS $2.50-2.65.
- Completed $110M ASR; $350M of $750M buyback executed; elected Barbara Duncan to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/halo-20230221.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer